[
  {
    "ts": null,
    "headline": "Johnson & Johnson (NYSE:JNJ) Submits sNDA For Schizophrenia Drug CAPLYTA® To FDA",
    "summary": "Johnson & Johnson (NYSE:JNJ) submitted a supplemental New Drug Application for CAPLYTA®, aiming to prevent schizophrenia relapse, marking a significant step in expanding its mental health portfolio. Over the last quarter, Johnson & Johnson's stock price increased by 4%. This movement aligns with the broader market trends, which have shown steady growth despite some trade uncertainties. The company's efforts in the pharmaceutical sector and robust earnings likely contributed positively to its...",
    "url": "https://finnhub.io/api/news?id=0dda058c5eb97ab0f86a5485aabe0905835e1f8076da4acf8c39439e820ce272",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1751995618,
      "headline": "Johnson & Johnson (NYSE:JNJ) Submits sNDA For Schizophrenia Drug CAPLYTA® To FDA",
      "id": 135829767,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "Johnson & Johnson (NYSE:JNJ) submitted a supplemental New Drug Application for CAPLYTA®, aiming to prevent schizophrenia relapse, marking a significant step in expanding its mental health portfolio. Over the last quarter, Johnson & Johnson's stock price increased by 4%. This movement aligns with the broader market trends, which have shown steady growth despite some trade uncertainties. The company's efforts in the pharmaceutical sector and robust earnings likely contributed positively to its...",
      "url": "https://finnhub.io/api/news?id=0dda058c5eb97ab0f86a5485aabe0905835e1f8076da4acf8c39439e820ce272"
    }
  },
  {
    "ts": null,
    "headline": "Trump says pharmaceutical tariffs could reach 200%",
    "summary": "U.S. President DonaldTrump on Tuesday said he plans to announce tariffs on importedpharmaceuticals which could reach 200% but he would givedrugmakers about one year to get their act together. ...",
    "url": "https://finnhub.io/api/news?id=ad58440456c926559c68bd2e6b6e91ab8c66b954068a94580d45ed2a4b2923e8",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1751994912,
      "headline": "Trump says pharmaceutical tariffs could reach 200%",
      "id": 135822191,
      "image": "",
      "related": "JNJ",
      "source": "Finnhub",
      "summary": "U.S. President DonaldTrump on Tuesday said he plans to announce tariffs on importedpharmaceuticals which could reach 200% but he would givedrugmakers about one year to get their act together. ...",
      "url": "https://finnhub.io/api/news?id=ad58440456c926559c68bd2e6b6e91ab8c66b954068a94580d45ed2a4b2923e8"
    }
  },
  {
    "ts": null,
    "headline": "How Will Skyrizi and Rinvoq Sales Aid AbbVie's Upcoming Q2 Results?",
    "summary": "ABBV leans on Skyrizi and Rinvoq sales strength to offset Humira's decline ahead of its Q2 earnings report.",
    "url": "https://finnhub.io/api/news?id=a18c12cd77ddee6772eeda08f133bcb8c233bd69bdcc839a042f8df8b92a629b",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1751977620,
      "headline": "How Will Skyrizi and Rinvoq Sales Aid AbbVie's Upcoming Q2 Results?",
      "id": 135805660,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "ABBV leans on Skyrizi and Rinvoq sales strength to offset Humira's decline ahead of its Q2 earnings report.",
      "url": "https://finnhub.io/api/news?id=a18c12cd77ddee6772eeda08f133bcb8c233bd69bdcc839a042f8df8b92a629b"
    }
  },
  {
    "ts": null,
    "headline": "Supplemental new drug application submitted to U.S. FDA for CAPLYTA® (lumateperone) with data demonstrating significant schizophrenia relapse prevention compared to placebo",
    "summary": "Johnson & Johnson (NYSE:JNJ) announced today the submission of a supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration (FDA) based upon long-term data evaluating the safety and efficacy of CAPLYTA® (lumateperone) for the prevention of relapse in schizophrenia. CAPLYTA® is the newest addition to Johnson & Johnson's portfolio of schizophrenia therapies, which now offers the broadest range of oral and long-acting injectable treatment options to support each patient's ind",
    "url": "https://finnhub.io/api/news?id=5243b80de315ea0759dfc163675e7ded82616c6cbf94d4b972bc4ad522cf5868",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1751976000,
      "headline": "Supplemental new drug application submitted to U.S. FDA for CAPLYTA® (lumateperone) with data demonstrating significant schizophrenia relapse prevention compared to placebo",
      "id": 135804223,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "Johnson & Johnson (NYSE:JNJ) announced today the submission of a supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration (FDA) based upon long-term data evaluating the safety and efficacy of CAPLYTA® (lumateperone) for the prevention of relapse in schizophrenia. CAPLYTA® is the newest addition to Johnson & Johnson's portfolio of schizophrenia therapies, which now offers the broadest range of oral and long-acting injectable treatment options to support each patient's ind",
      "url": "https://finnhub.io/api/news?id=5243b80de315ea0759dfc163675e7ded82616c6cbf94d4b972bc4ad522cf5868"
    }
  },
  {
    "ts": null,
    "headline": "IP Due Diligence: The Make-Or-Break Factor In Modern M&A",
    "summary": "As innovation cycles accelerate and technology convergence increases, intellectual property has become a powerful driver of major corporate acquisitions. For example, when Johnson & Johnson acquired...",
    "url": "https://finnhub.io/api/news?id=861e15b48b2fb4806d01b6cbbe80ef418e57cbbb3a1b18e5a840834d8db75487",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1751969471,
      "headline": "IP Due Diligence: The Make-Or-Break Factor In Modern M&A",
      "id": 135805160,
      "image": "",
      "related": "JNJ",
      "source": "Finnhub",
      "summary": "As innovation cycles accelerate and technology convergence increases, intellectual property has become a powerful driver of major corporate acquisitions. For example, when Johnson & Johnson acquired...",
      "url": "https://finnhub.io/api/news?id=861e15b48b2fb4806d01b6cbbe80ef418e57cbbb3a1b18e5a840834d8db75487"
    }
  },
  {
    "ts": null,
    "headline": "Analysis: 'Trump Effect' website takes credit for US investment made under Biden",
    "summary": "Since then, Trump has said the investments have swelled to $14 trillion, or roughly half of the nation's annual gross domestic product.  The White House calls it \"The Trump Effect\" and features a rolling list on its website of more than 70 projects it says Trump's economic policies spurred, from a new bakery plant in Texas to a LEGO facility in Virginia and a microchip plant in Arizona.",
    "url": "https://finnhub.io/api/news?id=92e2dc58d493ce2276eb1aaea4aa576578a366cd8c115d7728a13b84fa6525b0",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1751969010,
      "headline": "Analysis: 'Trump Effect' website takes credit for US investment made under Biden",
      "id": 135804198,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "Since then, Trump has said the investments have swelled to $14 trillion, or roughly half of the nation's annual gross domestic product.  The White House calls it \"The Trump Effect\" and features a rolling list on its website of more than 70 projects it says Trump's economic policies spurred, from a new bakery plant in Texas to a LEGO facility in Virginia and a microchip plant in Arizona.",
      "url": "https://finnhub.io/api/news?id=92e2dc58d493ce2276eb1aaea4aa576578a366cd8c115d7728a13b84fa6525b0"
    }
  },
  {
    "ts": null,
    "headline": "J&J: seeks FDA approval for Caplyta for schizophrenia",
    "summary": "Johnson & Johnson announces that it has submitted a supplemental new drug application to the US FDA for Caplyta for the prevention of relapse in patients with schizophrenia. This submission is based...",
    "url": "https://finnhub.io/api/news?id=6ec4e6eea98510f89872187183d5d9db7e776a04014300d3b4f07a807a9154c9",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1751966098,
      "headline": "J&J: seeks FDA approval for Caplyta for schizophrenia",
      "id": 135804661,
      "image": "",
      "related": "JNJ",
      "source": "Finnhub",
      "summary": "Johnson & Johnson announces that it has submitted a supplemental new drug application to the US FDA for Caplyta for the prevention of relapse in patients with schizophrenia. This submission is based...",
      "url": "https://finnhub.io/api/news?id=6ec4e6eea98510f89872187183d5d9db7e776a04014300d3b4f07a807a9154c9"
    }
  },
  {
    "ts": null,
    "headline": "Johnson & Johnson Announces the Submission of A Supplemental New Drug Application to the U.S. Food and Drug Administration Based Upon Long-Term Data Evaluating the Safety and Efficacy of Caplyta (Lumateperone) for the Prevention of Relapse in Schizophrenia",
    "summary": "Johnson & Johnson announced the submission of a supplemental New Drug Application to the U.S. Food and Drug Administration based upon long-term data evaluating the safety and efficacy of CAPLYTA®? ...",
    "url": "https://finnhub.io/api/news?id=ec641b67a28187a6d639ce59157d17da32b01772521999a7528a4fee0da8adb7",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1751964623,
      "headline": "Johnson & Johnson Announces the Submission of A Supplemental New Drug Application to the U.S. Food and Drug Administration Based Upon Long-Term Data Evaluating the Safety and Efficacy of Caplyta (Lumateperone) for the Prevention of Relapse in Schizophrenia",
      "id": 135804335,
      "image": "",
      "related": "JNJ",
      "source": "Finnhub",
      "summary": "Johnson & Johnson announced the submission of a supplemental New Drug Application to the U.S. Food and Drug Administration based upon long-term data evaluating the safety and efficacy of CAPLYTA®? ...",
      "url": "https://finnhub.io/api/news?id=ec641b67a28187a6d639ce59157d17da32b01772521999a7528a4fee0da8adb7"
    }
  },
  {
    "ts": null,
    "headline": "'Trump Effect' website takes credit for US investment made under Biden",
    "summary": "Within hours of taking office inJanuary, President Donald Trump boasted about attracting $3trillion in new corporate investments to the United States.Since then, Trump has said the investments have...",
    "url": "https://finnhub.io/api/news?id=d77bbae43c33414b021fb8f4beabeb6d30c80b5d9c8fbea15407ac3bc3d6ff2a",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1751954536,
      "headline": "'Trump Effect' website takes credit for US investment made under Biden",
      "id": 135802274,
      "image": "",
      "related": "JNJ",
      "source": "Finnhub",
      "summary": "Within hours of taking office inJanuary, President Donald Trump boasted about attracting $3trillion in new corporate investments to the United States.Since then, Trump has said the investments have...",
      "url": "https://finnhub.io/api/news?id=d77bbae43c33414b021fb8f4beabeb6d30c80b5d9c8fbea15407ac3bc3d6ff2a"
    }
  }
]